Unicycive Therapeutics (UNCY) Return on Capital Employed (2021 - 2026)
Unicycive Therapeutics posted quarterly Return on Capital Employed of 98.95% for Q1 2026, up 13638.0% year-on-year from N/an in Q1 2025, and down 3.69% on a QoQ basis from 95.42% in Q4 2025.
Unicycive Therapeutics (UNCY) has 6 years of Return on Capital Employed data on file, last reported at 98.95% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 13638.0% year-over-year to 98.95%; the trailing twelve-month figure through Mar 2026 stood at 98.95% (up 13638.0% YoY), and the FY2025 full-year result was 137.52%, down 283530.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 98.95%, down from 95.42% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 2895.47% in Q4 2023 and bottomed at 857.52% in Q1 2024.
- The 5-year median for Return on Capital Employed is 127.82% (2022), against an average of 70.64%.
- The widest annual swing landed in 2023, when Return on Capital Employed soared 345723 bps; it then plunged 318742 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 561.76% in 2022, then soared by 615 bps to 2895.47% in 2023, then tumbled by 110 bps to 291.95% in 2024, then jumped by 67 bps to 95.42% in 2025, then decreased by 4 bps to 98.95% in 2026.
- The last three Return on Capital Employed figures came in at 98.95% (Q1 2026), 95.42% (Q4 2025), and 116.13% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -98.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.95% |
| Dec 31, 2025 | -95.42% |
| Sep 30, 2025 | -116.13% |
| Jun 30, 2025 | -197.75% |
| Mar 31, 2025 | -235.33% |
| Dec 31, 2024 | -291.95% |
| Sep 30, 2024 | -93.55% |
| Jun 30, 2024 | -81.38% |
| Mar 31, 2024 | -857.52% |
| Dec 31, 2023 | 2,895.47% |
| Sep 30, 2023 | -346.74% |
| Jun 30, 2023 | -201.62% |
| Mar 31, 2023 | 1,949.69% |
| Dec 31, 2022 | -561.76% |
| Sep 30, 2022 | -259.08% |
| Jun 30, 2022 | -127.82% |
| Mar 31, 2022 | -79.35% |
| Dec 31, 2021 | -52.32% |
| Sep 30, 2021 | -72.60% |